Amicus Therapeutics · ISIN: US03152W1099

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm

Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company’s shareholders. Click here for additional information: https://kaskelalaw.com/case/amicus-therapeutics/ Since December 2023, shares of Amicus’ common stock have declined in value from a trading price of $14.50 per share...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 19.02.2025 | 21:18
19 February 2025 09:18PM
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company’s shareholders. Click here for additional information: https://kaskelalaw.com/case/amicus-therapeutics/ Since December 2023, shares of Amicus’ common stock have declined in value from a trading price of $14.50 per share...
© BusinessWire
19 February 2025 12:00PM
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year...
© Globe Newswire
10 February 2025 12:00PM
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024....
© Globe Newswire
03 February 2025 12:00PM
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025
PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at the 21st Annual WORLDSymposium™ 2025, being held February 3-7, 2025 in San Diego, CA....
© Globe Newswire
12 January 2025 09:00PM
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1...
© Globe Newswire
02 January 2025 12:00PM
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 3:00 p.m. PT....
© Globe Newswire
06 November 2024 12:00PM
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year...
© Globe Newswire
01 November 2024 11:00AM
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November....
© Globe Newswire
28 October 2024 11:00AM
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024....
© Globe Newswire
04 October 2024 11:00AM
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the 29th Annual Congress of the World Muscle Society being held October 8-12, 2024 in Prague, Czechia....
© Globe Newswire
17 September 2024 02:00PM
Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company’s shareholders. Since December 2023, shares of Amicus have declined in value from a trading price of $14.50 per share to a current trading price of approximately $11.00 per share, a decline of nearly 25% in value. The i...
© BusinessWire
03 September 2024 11:05AM
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September....
© Globe Newswire
30 August 2024 11:00AM
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September....
© Globe Newswire
08 August 2024 11:00AM
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
Q2 2024 Total Revenue of $126.7M, a 34% Increase Year-over-Year...
© Globe Newswire
05 June 2024 11:00AM
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T....
© Globe Newswire
04 June 2024 11:00AM
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Galien Foundation has awarded the 2024 Prix Galien U.K. Award for Best Pharmaceutical Product to Pombiliti® (c...
© Globe Newswire
09 May 2024 11:00AM
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
1Q 2024 Total Revenue of $110.4M, a 28% Increase Year-over-Year...
© Globe Newswire
01 May 2024 11:00AM
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 9, 2024, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2024....
© Globe Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.